Table 3.
Comparison of clinical symptoms in patients with MD treated with KD (group 1) and not treated with KD (group 2).
| Clinical Symptoms | No. of Patients in Whom Symptoms Was Observed/No. of All Patients (%) | All n = 21 |
|
|---|---|---|---|
| Group 1 MD + KD n = 11 |
Group 2 MD without KD n = 10 |
||
| Total IPMDS score reduction (clinical improvement) | 9/11 (81.8%) * | 2/10 (20%) | 11/21 (52.4%) |
| Reducing the number of seizures | 2/2 (100%) | 0/3 | 2/5 (40%) |
| Increased number of seizures | 0/5 | 2/5 | 2/10 (20%) |
| Reduction in the number of antiepileptic drugs | 2/5 (40%) | 0/5 | 2/10 (20%) |
| Improvement of muscle tone | 8/9 (88.8%) ** | 2/6 (33.3%) | 10/15 (66.6%) |
| Reduction in movement disorders (tremor, ataxia, dystonia) | 5/6 (83.3%) | 2/7 (28.6%) | 7/13 (53.8%) |
| Improved exercise tolerance | 8/11 (72.7%) ** | 1/7 (14.3%) | 9/18 (50%) |
| Decrease in rate of weight gain (by 2 percentiles or <3c) | 0/11 | 4/10 (40%) | 4/21 (19%) |
| Decrease in height gain rate (by 2 percentile channels or <3c) | 2/11 (18.2%) | 0/10 | 2/21 (9.5%) |
* Statistically significant difference p < 0.05, ** p < 0.1 (the chi-square test of independence with Yates correction). KD—ketogenic diet, MD—mitochondrial disease.